证券代码：688161 证券简称：威高骨科 公告编号：2024-032 山东威高骨科材料股份有限公司 重要内容提示： 山东威高骨科材料股份有限公司（以下简称"公司"）2023 年年度利润 分配方案中的每 10 股派发现金红利的金额由人民币 1.2 元（含税）调整为人民 币 1.2048 元（含税）。 本次调整原因：截止目前，公司已累计回购股份 1,597,266 股，致使可 参与权益分配的总股本发生变动，公司按照现金分红总额不变的原则，相应调整 2023 年度利润分配方案中的每股现金分红金额。 一、调整前利润分配方案 公司于 2024 年 3 月 25 日召开公司第三届董事会第八次会议、第三届监事会 第七次会议，并于 2024 年 4 月 29 日召开 2023 年年度股东大会审议通过了《2023 年年度利润分配预案的议案》，公司拟向全体股东每 10 股派发现金红利 1.20 元 （含税）。截至 2023 年 12 月 31 日，公司总股本为 400,000,000 股，以此计算拟 派发现金红利合计 48,000,000.00 元（含税）。本年度公司现金分红占归属于母 公司所有者的净利润的比例为 42.74% ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-031 二、实施回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应于每个月的前 3 个交 易日内公告截至上月末的回购进展情况，现将公司回购股份进展情况公告如下： 截至 2024 年 5 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购公司股份 1,597,266 股，占公司总股本 400,000,000.00 股的比 例为 0.399%，回购成交的最高价为 42.40 元/股，最低价为 28.59 元/股，支付 的资金总额为人民币 57,460,342.24 元（不含交易费用）。 山东威高骨科材料股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2024 年 5 月 31 日，山东威高骨科材料股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-030 山东威高骨科材料股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2024 年 4 月 30 日，山东威高骨科材料股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式已累计回购公司股份 1,597,266 股，占公司总股本 400,000,000.00 股的比例为 0.399%，回购成交的 最高价为 42.40 元/股，最低价为 28.59 元/股，支付的资金总额为人民币 57,460,342.24 元（不含交易费用）。 一、回购股份的基本情况 2023 年 8 月 28 日，公司召开第三届董事会第四次会议，审议通过了《关于 以集中竞价交易方式回购公司股份预案的议案》，同意公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股 股票，用于员工持股及/或股权激励计划。公司拟用于本次回购的资金总额不低 于人民币 6 ...

研究所： 证券分析师： 周小刚 S0350521090002 zhouxg@ghzq.com.cn [Table_Title] 业绩短期承压，创新驱动迈向新高峰 ——威高骨科（688161）2024 年一季报点评 投资要点: 风险提示。集采降价风险，新品放量不及预期，研发进展不及预期，欧 美市场销售不及预期，行业政策变动风险。 请务必阅读正文后免责条款部分 2 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------|--------|-------|--------|-------|----------------------|--------|-------|--------|------------| | [ 附 Ta 表 ble ： _F 威 or 高 ca 骨 st] 科盈利预测表 \n证券代码： | 688161 | | 股价： | 25.56 | 投资评级： | 增持 | | 日期： | 202 ...

Financial Performance - The company's net profit for Q1 2024 was CNY 35,851,783.23, a decrease from CNY 94,089,505.89 in the same period last year, resulting in a basic and diluted earnings per share of -62.50[10][24] - The company reported a decrease in operating profit to CNY 41,533,588.86 from CNY 110,203,029.47 in the previous year, reflecting challenges in the current market environment[24] - The net profit attributable to shareholders of the listed company decreased by 62.92% due to the implementation of centralized procurement prices for spinal products, compared to the previous year's prices[63] - The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, also decreased by 62.03% for the same reason[63] - The total comprehensive income attributable to the parent company was approximately CNY 34.91 million, down from CNY 94.14 million in the previous period[44] - Basic earnings per share for Q1 2024 were CNY 0.09, a decrease of 62.50% compared to the same period last year[83] Sales and Market Growth - The sales volume of the spinal product line increased by 58% year-on-year, driven by product structure optimization and enhanced brand influence through academic activities[16] - The sales volume of the orthopedic repair product line grew by over 50% year-on-year, reflecting an increase in market share due to expanded clinical coverage[17] - The company reported a rapid growth in overseas business, with sales increasing by over 35% year-on-year, focusing on key countries and enhancing product coverage[20] - Sales in the joint product line increased by over 30% year-on-year, driven by a combination of distribution and dealership models[35] - The company achieved a 26% year-on-year increase in sales for its trauma product line by enhancing logistics and collaboration with other product lines[69] - The company achieved a sales volume growth of over 3.5 times in the sports medicine product line, leveraging clinical channels and product synergy[93] Research and Development - Research and development expenses for Q1 2024 were CNY 29,532,012.18, compared to CNY 27,331,141.04 in the previous year, indicating a commitment to innovation[24] - Research and development expenses totaled 29,532,012.18, representing 8.49% of operating revenue, an increase of 1.48 percentage points year-over-year[28] - The company obtained 14 registration certificates during the reporting period, including 12 Class III certificates, focusing on emerging technologies and materials[71] - The company has completed certification for key products in the sports medicine product line, positioning itself in a mainstream research direction with biodegradable materials[18] - The company plans to promote the application of 3D printing technology in various products, including fusion devices, knee joints, shoulder joints, and customized tumor products[95] Regulatory Approvals - The company received regulatory approval for the "Bone Filling Bag System" and "Titanium Coated Interbody Fusion Device," which are expected to enhance clinical outcomes and market potential[37] - The company received regulatory approval for its "artificial hip joint prosthesis trabecular acetabular cup system" and "artificial hip joint prosthesis dual-mobility acetabular system" during the reporting period[95] - The dual-mobility acetabular system is the first of its kind certified in China, designed to better simulate the natural range of motion of the hip joint, enhancing post-operative quality of life for patients[95] Financial Position - Total assets at the end of the reporting period were 5,052,214,390.30, a decrease of 0.87% from 5,096,573,977.62 at the end of the previous year[28] - The total liabilities amounted to 1,163,210,409.28, down from 1,222,459,156.70 in the previous period[42] - The company's equity attributable to shareholders increased by 0.36% to 3,882,861,298.62 from 3,868,918,255.96 at the end of the previous year[28] - Total liabilities and shareholders' equity amounted to CNY 5.05 billion, a decrease from CNY 5.10 billion at the end of the previous year[50] Cash Flow - The net cash flow from financing activities of -16,453,656.74, a significant decrease compared to -1,721,027.11 from the previous period[26] - The net cash flow from operating activities decreased by 55.18%, primarily due to reduced revenue from spinal products following the price changes[63] - Cash inflow from investment activities for Q1 2024 was CNY 245,450,442.70, while cash outflow was CNY 267,587,746.68, resulting in a net cash flow of -CNY 22,137,303.98[78] - The net increase in cash and cash equivalents was -23,373,007.47, compared to -655,777,987.96 in the previous period[26] Operational Efficiency - The company optimized its manufacturing structure and resource allocation, improving operational efficiency and controlling production costs[39] - The company is focusing on optimizing product structure and enhancing profitability and turnover rates across its orthopedic product lines[92] - The company is expanding its product registration efforts in 11 countries, including Brazil and Saudi Arabia, to enhance its international market presence[20] - The company aims to strengthen its brand trust among orthopedic doctors through academic exchanges and collaborations with hospitals[20]

证券代码：688161 证券简称：威高骨科 山东威高骨科材料股份有限公司 2023 年年度股东大会 会议资料 二零二四年四月 山东威高骨科材料股份有限公司 2023 年年度股东大会会议资料 目录 | 2023 | 年年度股东大会会议须知 | 1 | | --- | --- | --- | | 2023 | 年年度股东大会会议议程 | 3 | | 2023 | 年年度股东大会会议议案 | 5 | | | 关于《2023 年度董事会工作报告》的议案 | 5 | | | 关于《2023 年度监事会工作报告》的议案 10 | | | | 关于《公司 2023 年度财务决算报告》的议案 13 | | | 关于公司 | 2023 年度利润分配预案的议案 16 | | | | 关于授权董事会进行 2024 年度中期分红的议案 17 | | | | 关于公司《2023 年年度报告》及摘要的议案 18 | | | | 关于预计公司 2024 年度日常关联交易的议案 19 | | | 关于公司 | 2024 年度董事、监事薪酬的议案 26 | | | | 关于公司未来三年（2024 年-2026 年）股东分红回报规划的议案 29 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-028 山东威高骨科材料股份有限公司 关于 2023 年年度股东大会取消议案暨 2023 年年度股 东大会补充通知的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 1、 股东大会的类型和届次： 2023 年年度股东大会 1、 取消议案名称 | 序号 | 议案名称 | | --- | --- | | 8 | 《关于公司拟续聘会计师事务所的议案》 | 2、 取消议案原因 公司于 2024 年 4 月 19 日召开第三届董事会第九次会议，审议通过了《关于 取消 2023 年年度股东大会部分提案的议案》。公司于 2024 年 3 月 25 日召开第三 届董事会第八次会议，审议通过了《关于提请召开公司 2023 年年度股东大会的 议案》，公司将需股东大会审议的相关议案与股东进行了预沟通，根据预沟通的 结果，基于谨慎性考虑，公司取消 2023 年年度股东大会中第 8 项提案，即《关 2、 股东大会召开日期：2024 年 4 月 29 日 3、 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-027 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担责任。 山东威高骨科材料股份有限公司 关于参加 2023 年度医用耗材行业集体业绩说明会的公告 重要内容提示： 山东威高骨科材料股份有限公司（以下简称"公司"）已于 2024 年 3 月 27 日发布公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年 度经营成果、财务状况，公司计划于 2024 年 4 月 18 日下午 03:00-05:00 举行 2023 年年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 三、参加人员 会议召开时间：2024 年 4 月 18 日（星期四）下午 03:00-05:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 ...

Investment Rating - The investment rating for the company is "Accumulate" [2][4]. Core Views - The company's performance in 2023 was significantly impacted by the implementation of volume-based procurement, leading to a decrease in ex-factory prices and channel inventory adjustments. Revenue for 2023 was 1.284 billion yuan, a year-on-year decline of 37.6%, while net profit attributable to shareholders was 112 million yuan, down 81.3% year-on-year. The fourth quarter alone saw a revenue drop of 55.8% to 201 million yuan, with a net loss of 10 million yuan [2][7][26]. - The appointment of Chen Min as the new chairperson is expected to drive the company towards becoming a global leader in orthopedic innovation and technology, enhancing its internationalization strategy and sales channel development [2][7]. - The company has experienced pressure across all business lines, with significant revenue declines in spinal products (48.5%), trauma products (53.9%), and joint products (35.3%). However, the sports medicine and tissue repair products have emerged as important revenue sources, generating 227 million yuan in 2023 [2][13][26]. Financial Performance Summary - Revenue and Profit Forecasts: - 2024-2026 projected net profits are 250 million, 328 million, and 390 million yuan, representing year-on-year growth rates of 122.2%, 31.6%, and 18.8% respectively. Earnings per share (EPS) are expected to be 0.62, 0.82, and 0.98 yuan [2][3][38]. - Key Financial Metrics: - 2023 revenue was 1.284 billion yuan, with a gross margin of 66.5%, down 8.3 percentage points from the previous year. The net profit margin fell to 8.8%, a decrease of 20.6 percentage points [2][26][39]. - R&D Investment: - The company maintained a high level of R&D investment, with expenses reaching 130 million yuan in 2023, a 10.7% increase year-on-year, representing a R&D expense ratio of 10.1% [19][26]. Business Line Performance - Revenue Breakdown: - Spinal products generated 472 million yuan, trauma products 195 million yuan, and joint products 289 million yuan in 2023. The sports medicine and tissue repair segment achieved 326 million yuan, marking a significant growth area [2][13][36]. - Future Growth Expectations: - The company anticipates a return to normal growth rates as ex-factory prices stabilize and channel inventory is cleared. The expected revenue for 2024 is 1.502 billion yuan, reflecting a 17% increase [2][3][38].

华泰联合证券有限责任公司 关于山东威高骨科材料股份有限公司 2023 年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：威高骨科 | | --- | --- | | 保荐代表人姓名：唐澍 | 联系电话：025-83387919 | | 保荐代表人姓名：唐逸凡 | 联系电话：025-83387720 | 二、重大风险事项 售价格持续下降或市场占有率下降的风险，进而可能对公司未来盈利能力产生不 利影响，甚至可能产生业绩大幅下滑或亏损的风险。 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为山东威高骨科材料股份有限公司 （以下简称"威高骨科"、"公司"或"发行人"）首次公开发行股票的保荐机 构，对威高骨科进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 无。 公司当前面临的主要风险因素如下： （二）核心竞争力风险 （一）业绩大幅下滑或亏损的风险 国家集采政策逐步推进对骨科行业影响深远，带量采购使产品入院价格大幅 ...